Australian shares dip in broad-based selling; South32 shines
The S&P/ASX 200 index fell 0.6 per cent to 8,700.80 by 0023 GMT. The benchmark rose 2.1 per cent last week in its strongest weekly performance since April.
Globally, investors were hoping for some progress in trade talks ahead of US President Donald Trump's August 1 tariff deadline.
In Sydney, miners fell 0.4 per cent on Monday after gaining 1.7 per cent last week. Shares of mining major BHP were down 0.2 per cent.
Outperforming the mining sub-index, South32 rose more than 2 per cent after the world's largest producer of manganese clocked an output of 1.1 million wet metric tons of manganese for the quarter ended June 30. The result beat a Visible Alpha consensus estimate of 850,000 wmt, as per Barrenjoey.
Financials dropped 0.8 per cent after rising 1.6 per cent last week, with the "Big Four" banks down between 0.6 per cent and 1.1 per cent.
Gold stocks declined more than 1 per cent. Northern Star Resources and Genesis Minerals lost 0.5 per cent and 1.5 per cent, respectively.
Energy stocks fell 0.3 per cent. Woodside Energy was down 0.3 per cent, while Santos edged 0.1 per cent lower.
Brent crude futures rose 5 cents to US$69.33 a barrel after settling 0.35 per cent lower on Friday. US West Texas Intermediate crude was up 2 cents at US$67.36 a barrel, following a 0.30 per cent decline in the previous session.
Information technology stocks dropped 0.3 per cent. WiseTech Global declined 0.2 per cent, while Xero's Australian shares shed 0.7 per cent.
New Zealand's benchmark S&P/NZX 50 index rose 0.2 per cent to 12,905.69.
Data showed the country's annual consumer inflation accelerated in the second quarter but came in below economists' forecasts.
The Reserve Bank of New Zealand, which in May forecast annual inflation for the quarter at 2.6 per cent, held interest rates steady at this month's policy meeting partly due to near-term price risks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 hours ago
- The Star
US, NATO developing novel funding mechanism for Ukraine weapons transfers
WASHINGTON (Reuters) -The United States and NATO are working on a novel approach to supply Ukraine with weapons using funds from NATO countries to pay for the purchase or transfer of U.S. arms, according to three sources familiar with the matter. The renewed transatlantic cooperation on Ukraine comes as U.S. President Donald Trump has expressed frustration with Moscow's ongoing attacks on its neighbor. Trump, who initially took a more conciliatory tone toward Russia as he tried to end the more than three-year war in Ukraine, has threatened to start imposing tariffs and other measures if Moscow shows no progress toward ending the conflict by August 8. The president said last month the U.S. would supply weapons to Ukraine, paid for by European allies, but did not indicate how this would be done. NATO countries, Ukraine, and the United States are developing a new mechanism that will focus on getting U.S. weapons to Ukraine from the Priority Ukraine Requirements List, known under the acronym PURL, the sources said. Ukraine would prioritize the weapons it needs intranches of roughly $500 million, and NATO allies - coordinated by NATO Secretary General Mark Rutte - would then negotiate among themselves who would donate or pay for items on the list. Through this approach, NATOallies hope to provide $10 billion in arms for Ukraine, said a European official, speaking on condition of anonymity. It was unclear over what timeframe they hope to supply the arms. "That is the starting point, and it's an ambitious target that we're working towards. We're currently on that trajectory. We support the ambition. We need that sort of volume," the European official said. NATO declined to comment. The White House, Pentagon, and Ukrainian embassy in Washington did not respond to requests for comment. Russian forces are gradually advancing against Ukraine, and control one-fifth of Ukraine's territory. FASTER ARMS RESTOCKING If a NATO country decides to donate weapons to Ukraine, the mechanism would allow that country to effectively bypass lengthy U.S. arms sales procedures to replenish its own stocks, said one U.S. official, speaking on condition of anonymity. But the NATO country would have to pay the U.S. up front for the speedier replenishment. The money would be paid into a U.S.-held account, possibly at the U.S. Treasury Department, or to an escrow fund, although the exact structure remains unclear, the official said. NATO countries also have the option of simply paying the United States to send weapons directly to Ukraine. In that case, the payment could be made via NATO or directly to the U.S. Department of Defense, said a second source, speaking on condition of anonymity. This would be in addition to the United States' own effort to identify arms from U.S. stockpiles to send to Ukraine under the Presidential Drawdown Authority, which allows the U.S. president to draw from current weapons stocks to help allies in an emergency. At least one tranche of weapons for Ukraine is currently being negotiatedunder the new mechanism, two sources said, though it was unclear if any money has yet been transferred. Trump's fellow Republicans in Congress have introduced legislation, known as the PEACE Act, that aims to create a fund at the U.S. Treasury in which allies can deposit money that would pay to replenish U.S. military equipment donated to Ukraine. Ukraine's needs remain consistent with previous months - air defenses, interceptors, systems, rockets, and artillery. The last statement of need from Ukraine came at the July 21 Ramstein conference led by EU allies, including Britain. (Reporting by Gram Slattery, Mike Stone, Phil Stewart in Washington; additional reporting by Patricia Zengerle in Washington and Andrew Gray in Brussels; editing by Michelle Nichols and Rod Nickel)
The Star
3 hours ago
- The Star
Britain's manufacturing contraction eases in July but outlook remains weak
LONDON, Aug. 1 (Xinhua) -- Britain's manufacturing downturn showed signs of easing in July, with the seasonally adjusted Manufacturing Purchasing Managers' Index (PMI) rising to a six-month high of 48, according to data released by S&P Global on Friday. The July PMI was slightly higher than 47.7 in June, but the index has now signalled contraction for ten consecutive months. S&P Global noted that risks persist, including fragile domestic and overseas market conditions, subdued consumer confidence, and manufacturers' ongoing concerns about costs. Market conditions remained subdued in July as British manufacturers reported weak spending willingness and low confidence at home and abroad. Rob Dobson, director at S&P Global Market Intelligence, said although the UK manufacturing sector is starting to send some tentatively encouraging signals, there's no assured path back to strong growth. Domestic clients are unwilling to spend due to cost rises triggered by higher minimum wages and employer national insurance contributions, while export markets are being buffeted by geopolitical stresses as well as trade and tariff uncertainties. The data also showed that new export orders have decreased over the past three and a half years. Additionally, the sector faced a weak labor market in July. The company attributed this to a combination of weak demand, rising staff costs, and subdued market confidence. Job losses were recorded for the ninth month in a row, with the pace of reductions over the past six months ranking among the sharpest since 2020, when the country was hit by the COVID-19 pandemic.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
IRVINE, Calif. and QUEENSLAND, Australia, Aug. 1, 2025 /PRNewswire/ — ELIXIR MD, Inc., a pioneer in advanced medical technology and proprietary treatment protocols for plastic surgery, today announced the formation of its wholly owned subsidiary in Australia and New Zealand, alongside an exclusive partnership with High Tech Medical Pty Ltd. to launch the ELIXIR MD™ device across the region. Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.' Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.' Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph). About High Tech Medical Pty in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence. About ELIXIR MD, in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide.
